{
    "clinical_study": {
        "@rank": "83861", 
        "arm_group": [
            {
                "arm_group_label": "Chronic atrial fibrillation, active drug", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient (n=10) with chronic atrial fibrillation who are randomized to colchicine"
            }, 
            {
                "arm_group_label": "Chronic atrial fibrillation,  placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients with chronic atrial fibrillation (n=10) who are randomized to placebo."
            }, 
            {
                "arm_group_label": "Pre-ablation, sinus rhythm,  drug", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with paroxysmal atrial fibrillation presenting for catheter ablation in sinus rhythm (n=10) who are randomized to colchicine"
            }, 
            {
                "arm_group_label": "Pre-ablation, sinus rhythm, placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients with paroxysmal atrial fibrillation presenting for catheter ablation in sinus rhythm (n=10) who are randomized to placebo"
            }, 
            {
                "arm_group_label": "Pre-ablation, atrial fibrillation, drug", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients presenting for atrial fibrillation catheter ablation in atrial fibrillation (n=10) who are randomized to colchicine"
            }, 
            {
                "arm_group_label": "Pre-ablation, atrial fibrillation, placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients presenting for atrial fibrillation catheter ablation in atrial fibrillation (n=10) who are randomized to placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the\n      rise in CRP which occurs following atrial fibrillation ablation"
        }, 
        "brief_title": "Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation and Post AF Ablation", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Ablation", 
            "C Reactive Protein"
        ], 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices.\n             Diagnosis of AF will be made based on the 12 -lead surface ECG.\n\n          -  Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the\n             electrophysiology laboratory for the procedure in sinus rhythm..\n\n          -  Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting\n             in the electrophysiology laboratory in atrial fibrillation .\n\n        Exclusion Criteria:\n\n          1. Abnormal liver function with elevated enzymes> 1.5 times the normal.\n\n          2. Abnormal kidney function with glomerular filtration rate < 50 ml/min\n\n          3. Increased levels of creatine kinase or known myopathy\n\n          4. Neutropenia\n\n          5. Known GI disorders\n\n          6. Women of childbearing age who have not had surgical sterilization and are not using\n             oral contraceptives, or who's spouse has not had surgical sterilization will be\n             excluded due to the length of the trial and the possibility that they could become\n             pregnant after entry.\n\n          7. Pregnant and lactating women\n\n          8. Lactose intolerance\n\n          9. Known sensitivity, allergy, or contraindication to colchicine use -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755949", 
            "org_study_id": "12-001686"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Chronic atrial fibrillation, active drug", 
                    "Pre-ablation, sinus rhythm,  drug", 
                    "Pre-ablation, atrial fibrillation, drug"
                ], 
                "description": "Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo", 
                "intervention_name": "Colchicine, 0.6 mg PO BID", 
                "intervention_type": "Drug", 
                "other_name": "Colcrys"
            }, 
            {
                "arm_group_label": [
                    "Chronic atrial fibrillation,  placebo", 
                    "Pre-ablation, sinus rhythm, placebo", 
                    "Pre-ablation, atrial fibrillation, placebo"
                ], 
                "description": "Placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug", 
                "intervention_name": "Matching placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Colchicine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "atrial fibrillation", 
            "catheter ablation", 
            "colchicine", 
            "c reactive protein", 
            "CRP"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "email": "kontras.dana@mayo.edu", 
                "last_name": "Dana g. Kontras, RN", 
                "phone": "904-953-8577"
            }, 
            "facility": {
                "address": {
                    "city": "Jacksonville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32224"
                }, 
                "name": "Mayo Clinic Florida"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation (AF) and Post AF Ablation", 
        "overall_contact": {
            "email": "kontras.dana@mayo.edu", 
            "last_name": "Dana G. Kontras, RN", 
            "phone": "904 953-8577"
        }, 
        "overall_official": {
            "affiliation": "Consultant in Cardiovascular Diseases", 
            "last_name": "Joseph L. Blackshear, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Three groups of atrial fibrillation patients, 20 per group, will be randomized to receive colchicine or matching placebo for one month, and have intensive monitoring of c-reactive protein during the month.", 
            "measure": "C-reactive protein", 
            "safety_issue": "No", 
            "time_frame": "one month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755949"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Joseph L. Blackshear", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "All patients will have 12 lead ECG obtained one month after study enrollment", 
            "measure": "Sinus rhythm on ECG", 
            "safety_issue": "No", 
            "time_frame": "One month"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}